

November 17, 2011

News Release

Company: Olympus Corporation
Representative Director, President and CEO: Shuichi Takayama
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Akihiro Nambu, Manager, Public Relations and IR Office

Notice Concerning Additional Information Regarding Deferred Posting of Losses and Filing of Second Quarterly Report for Fiscal Year Ending March 31, 2012

Olympus Corporation (the “Company”) hereby announces additional information regarding its deferred posting of losses, as announced on November 8, 2011 and Delay in Filing of Second Quarterly Report for Fiscal Year Ending March 31, 2012, as announced on November 10, 2011.

1. Filing of Second Quarterly Report for Fiscal Year Ending March 31, 2012

The Company is preparing to file the Second Quarterly Report promptly upon receipt of the investigation report from the Third Party Committee in early December 2011. The Company has already set up a special project team of external experts and is using the support of related parties to prepare the financial report in a timely manner. The Company is planning to file the Second Quarterly Report by December 14, after receiving a review statement from its accounting auditor.

2. Corrections of Past Financial Statements

It has become necessary for the Company, while preparing its Second Quarter Financial Statements for the Fiscal Year Ending March 2012, as stated the above, to also file amended financial statements for previous years. While the media have been reporting on this matter, it is important to note that these reports are not based on official statements from the Company. Preparations are now underway to produce these amended statements, including such details as the year from which statements must be amended. The Company will promptly disclose such details as they become available.

3. Olympus Briefing for Financial Institutions on November 16, 2011

The Company met with financial institutions on November 16, 2011 to explain the details of its current situation and related developments, as well as its current financial status on management accounting basis. Please refer to “Briefing for Financial Institutions” for additional information.

Please be informed that the “Briefing for Financial Institutions” is based on facts and financial information as currently understood by the Company. Details of the Company’s financial information is subject to change, as the Company verifies the facts based on investigation results by the Third Party Committee, which was established on November 1, 2011. The Company will promptly carry out the timely disclosure of all appropriate information along with the Second Quarterly Report after receiving the investigation report from the Third Party Committee.

The Company would like to take this opportunity to sincerely offer its deepest apologies to shareholders, investors, business partners, customers and other relevant parties for all inconvenience caused.

- END -

OLYMPUS

Your Vision, Our Future

**Supplemental Information
(Presentation material related to the “Timely
Disclosure” at TSE)**

Briefing for Financial Institutions

**Meeting held on November 16, 2011
Olympus Corporation**

Contents

1. The Current Situation and Related Developments
2. Business Segments
3. Business Results
4. Financial Status
5. Q&A

The contents of this conference is based on the facts we are aware of at the moment. Please be aware that our financial status report might be revised after receiving the investigation report from the Third Party Committee established on November 1st 2011.

1. The Current Situation and Related Developments

Details regarding recent reports

- Due to the October 14 report on change in presidency and the fall on stock price, Olympus decided to transfer a representative director on October 26. Tsuyoshi Kikukawa resigned the post of the Chairman, President and CEO and gave back a representation right. **Shuichi Takayama has been appointed as a Representative Director, President and CEO.**
- On October 27, **the additional information about the past acquisition was disclosed.**
- On November 1 , an independent panel of **third party committee** was established and first meeting was held.
- On November 8, while the Third Party Committee was proceeding with its investigation, the company discovered that it **had deferred the posting of losses.** Thereafter, the company held a press conference to disclose this information and dismissed Executive Vice President Hisashi Mori. Hideo Yamada informed the company that he was intending to resign.

Details regarding the past losses

Our understanding

- **Former Executive Vice President Mori has explained the details:**

- **Olympus incurred losses on investments dating to the 1990s**
- **Used multiple funds to cover up the losses**
- **The payment made with regards to the acquisition of Gyrus Group, and three domestic companies were used to make up for the loss.**
- **None of the funds are used for money laundering or for an antisocial organization.**

**The facts will be revealed by the investigation
of a Third Party Committee**

The Third Party Committee

The investigation by the committee consists of external experts who does not have any relationship with Olympus started the investigation from November 1. The final report is expected to be **released at the beginning of December**

- The Third Party Committee**
- **Purpose:**
 - Investigate whether Olympus had an inaccurate management decision which carried out illegal and inappropriate act on past acquisitions (Gyrus and three domestic companies).
 - Investigate the facts concerning hiding of losses
 - The proposal on the improvement and strengthening of the corporate governance
 - **Members:**
 - Chairperson - attorney-at-law Kainaka (former Justice of the Supreme Court, former Superintending Prosecutor of Tokyo High Public Prosecutors' Office)
 - **Committee :**
 - Mr. Nakagome, attorney-at-law (a former president of Nagoya Chief Judge of the High Court)
 - Mr. Arita, attorney-at-law (a former Fukuoka High Public Prosecutor's Office superintendent public prosecutor)
 - Mr. Sudoh, attorney-at-law
 - Mr. Katayama, attorney-at-law
 - Mr. Takiguchi, Certified public accountant

Olympus:

Full cooperation to submit all the information to the committee

- Presentation of related data
- Hearing of related parties

Committee liaison team

OLYMPUS

Committee:

Commitment to discover the truth

- Through investigation with independency
- Propose improvement plans

For Continued Listing

Actions for continued listing

Nov 10th :

- ▶ Tokyo Stock Exchange designated Olympus stock as a “security under supervision (confirmation)” due to the delay in filing of second quarterly report for FY2011 by the due date of November 14, 2011, pursuant to the FIEA.

Early Dec:

- ▶ **After receiving the investigation reports from the Third Party Committee,** an action plan will be announced. (Olympus will clarify where the responsibility lies and will take necessary legal actions)

By Dec 14th :

- ▶ File the second quarterly report by Dec 14th, no later than one month after the legal deadline which is a criteria of delisting.

Enhancement of Corporate Governance

Problems and Issues that Olympus Realizes

- **Centralized authority to the top management and the long status quo**
- **Process of decision making at the executive management meeting and the board meeting**
- **Vulnerability of supervisory function of management**
- **Disclosure to the stakeholders, etc**

We will fully cooperate closely with the investigation by the Third Party Committee, and sincerely accept the report and proposal to improve our corporate governance. Also, we will establish a new management with support by independent experts and adopt any measures to improve our governance as quickly as we can.

2. Business Segments


Advantage of technology and dominant share (70%) ensure profitability and steady growth

Future Tactics

- Rapidly introduce and popularize next-generation endoscope systems
- Establish significant presence in emerging markets with competitive pricing

Strengths and features

- Only medical devices in this field capable of both diagnosis and treatment
- Exquisite images to be displayed on HD monitor in real time
- State of the art technologies, such as narrow-band imaging (NBI), for promoting early detection of cancer



Endoscopic system

Medical: Growth Strategy 2 – Surgical and Endo-Therapy Areas

Launch of new “synergy” products (electric knives) offering merits of Olympus and Gyrus technologies planned in this Fiscal Year


Synergy effect and potentials of Gyrus

- Develop market through minimally invasive surgical operation procedures and launch new high value-added devices
- Expand disposable supplies business
- Establish and utilize training centers

Strength and Feature of Gyrus

- Dominant shares in N. America for minimally invasive urology & gynecology equipments

Overseas Growth of Surgical and Endo-therapy Devices (unit: million yen)



Year ended March 2011
Growth rate after adjustment figures excluded impact of FX (12.5 billion yen): **+10%**

Year ended March 2010
Growth rate after adjustment figures excluded impact of FX (11.7 billion yen): **-2%**
Temporary negative impact due to restructuring of Gyrus for improved efficiency.





Expansion of China and Other Emerging Markets

- Introduce popularly priced models
 - ✓ Strengthen sales and service structures
 - Established a local subsidiary in India
- Expand market size and share
 - ✓ Increase the number of endoscopists technicians and improve their skills by training
 - 2008: Shanghai Training Center
 - 2010: Established Beijing Training Center



Beijing Training Center

Net Sales in China/Asia



*From medium-term business plan announced on May 12, 2010

Medical: Growth Strategy 4 – Annual Sales of ¥1 Trillion within 10 Years

Achieving 10-Year Goals of annual sales of ¥1 trillion
by fiscal year ending March 31, 2020* *Olympus centennial

Expansion of Diagnostic and Treatment Fields


- Expansion in orthopedic surgery and cardiovascular business

Average Annual Growth Rate: Approx. 11%
 (March 2011 - March 2020)

- Growth driver: surgical & endotherapy devices

Products		Product group				
		Endoscopes	...	Energy products	...	Solution services
Diagnostic fields	Gastrointestinal (internal)					
	Respiratory					
	General surgery					
	Urology					
	Ear and nose					
	Orthopedic surgery					
	cardiovascular					

(Unit: Billion yen)



Note) Figures from March 2011 to March 2015 :announced on medium-term plan dated May 12, 2010
 Figures from March 2016 to 2020: target figure

Medical: Messages from Doctors (Abstract)

- *“Your technological leadership, contributions to the medical industry and trust from doctors won’t change.”*
- *“You have excellent human resources, R&D capabilities and world-class accomplishments.”*
- *“Your products have saved many lives. I am hoping you will overcome this difficult situation using your unmatched assets.”*
- *“Your contributions to society have been great. Diagnosis and treatment for gastrointestinal cancer using your endoscopic system has made early-stage cancer treatment possible. Please overcome this and take pride in your achievements.”*
- *“Do not be afraid. Your products are trusted worldwide. Furthermore, you have strong human resources and know-how. Patients and users believe in you. I believe in you.”*
- *“Olympus and other members of medical society have led the development and evolvement of endoscopes in our country. Japanese endoscopic therapy leads the world. Olympus products are favored around the globe. People must note that patients would be hurt the most and endoscopic therapy quality could decline.”*

Imaging: Improve Profitability in This Fiscal Year

Build structure for sustainable profits

- Improve supply chain and inventory control
- Cost cutting initiatives

Strengthen product appeal

- Product development harnessing optical technologies (SZ-30MR)
- More value-added profitable products (3rd-generation OLYMPUS PEN series)



Expand line-up of *Micro Four Thirds 'PEN' Series* and value-added features and accessories




High-end compact 'XZ-1' Mount SLR 'ZUIKO' lens



High-power compact 'SZ-30MR' 16-megapixel CMOS sensor, 24x optical zoom, full HD video

Operating Profit (Unit: billion yen)




Move into the black

Imaging: Further Growth in Mirrorless Digital Camera Market

Olympus was the first to introduce a mirrorless camera, the OLYMPUS PEN, which sales is very well.

- Achieved top ranking (38.7%) at “BCN ranking” in mirrorless camera category in first half of 2011 (January to June)
- 3rd generation PEN “E-P3” launched in July ranked second at BCN ranking in interchangeable camera category. *Weekly data including first day of release date




3rd generation OLYMPUS PEN Series



Strengths and features


- **Top-class shares** in each domain (Biological Microscopes - 60% (competitors: Nikon and Leica), Ultrasound and Electromagnetic non-destruction testing system - 35% and Industrial videoscopes -- 40%, (competitor: GE for both)
- **Common infrastructure for optical technology, R&D and production**
- **Overall global offering of many integrated and networked technologies** for examination and analysis
- Creating **synergy effects in cost and efficiency** leading to **competitive differentiation**



Highly profitable structure

- **Stable profits:** Reduced yen's forex risk via expanded global R&D production
- **Overwhelming technological strengths and steady growth**

Operating profit



Note: Some business reclassified to Life Science & Industrial from 2011/3.

Business

- Sales of mobile phones and fixed lines


Mobile phone sales market

- Market expansion for devices such as smartphones, tablets, etc.


Results

- Market share: approx. 6% (#2 in industry)
- Increased income and profit for three consecutive terms

Growth of the market in units of sales



Operating profit



3. Financial Results

Basis for the Figures (Premises)

Management Basis

Figure used for the business management and the performance evaluation. It is mainly used to analyze through the comparison of business plans.

For internal management, quick response is crucial.

-Range of Conduct-

Profit and Losses sales - operating profit

Balancing Factors receivables, inventory, accounts payable

Accounting Basis (Disclosure Basis)

Using GAAP as its foundation, it is the financial accounting figures in financial reports and brief notes on the settlement of accounts.

-Range of Conduct-

earning statements, position statements, statements of cash flows

Differences between the Operating Profit Level on the Management Basis and the Accounting Basis

Summary estimates mainly used for management basis

- Sales profit and operating profit : Cost variance adjustment is not included in the management basis
- Sales expenses and SG&A : Finalized amount of the retirement benefit is not included in the management basis

Our second quarter performance and the current quarter forecast are explained in the following slides using our management basis figures

Summary of the Financial Report (Management Basis)

◆ The First Half of the FY Ending March 2012 (April – September, 2011)

(Unit: billion yen)

	(1) 1H of FY Ended March 2011 (actual)	(2) 1H of FY March 2012 (planned)	(3) 1H of FY March 2012 (actual)	(3)-(1) Difference from the same period of pervious year	(3)-(2) Difference from the plan
Net Sales	418.8	421.1	416.3	(2.5)	(4.8)
Operating Income	19.8	14.7	16.9	(2.9)	+2.2
OP ratio to sales	4.7%	3.5%	4.1%	(0.6%)	+0.6%
Exchange Rate					
USD	88.95 yen	85.00 yen	79.82 yen	(9.13) yen	(5.18) yen
EUR	113.85 yen	110.00 yen	113.79 yen	(0.06) yen	+3.79 yen
Impact from the Exchange Rate					
Net Sales	-	-	-	(13.1)	(3.6)
Operating Income	-	-	-	(1.6)	+0.3

Segment (1) (Management Basis)

◆ The First Half of the FY Ending March 2012 (April – September, 2011)

(Unit: billion yen)

		(1) 1H of FY Ended March 2011 (actual)		(2) 1H of FY March 2012 (planned)		(2)-(1) Differences		FX Impact in the Differences
Net Sales	Consolidated	418.8	-	416.3	-	(2.5)	-	(13.1)
	Medical	175.5	-	164	-	(11.5)	-	(8.1)
	Life Science & Industrial	42.8	-	44.9	-	+2.1	-	(2.4)
	Imaging	68.2	-	71.1	-	+2.9	-	(2.6)
	Information & Communication	102.4	-	109.2	-	+6.8	-	-
	Others	29.9	-	27.1	-	(2.8)	-	-
Operating Income and OP Ratio to Net Sales	Consolidated	19.8	4.7%	16.9	4.1%	(2.9)	(0.6%)	(1.6)
	Medical	36.6	20.8%	30.2	18.4%	(6.4)	(2.4)%	(3.0)
	Life Science & Industrial	2.2	5.2%	2.4	5.3%	+0.2	+0.1%	(1.1)
	Imaging	(4.1)	(6.0)%	0.5	0.7%	+4.6	+6.7%	+2.2
	Information & Communication	2.8	2.8%	.29	2.7%	+0.1	(0.1)%	-
	Others	(17.7)	-	(19.1)	-	(1.4)	-	+3

Segment (2) (Management Basis)

◆ Receivables, Inventory and Accounts Payable

(Unit: billion yen)

		(1) Results at the end of Sept. 2010	(2) Results at the end of Sept. 2011	(2)-(1) Differences	(Reference) Results at the end of Mar. 2011
Receivables	Total	118.4	114.9	(3.5)	128.2
	Medical	63.6	57.6	(6)	66.4
	Life Science & Industrial	16.2	15.3	(0.9)	17.4
	Imaging	21.9	23.7	+1.8	18.8
	Information & Communication	16.7	18.3	+1.6	25.6
Inventory	Total	91.5	97.7	+6.2	88.6
	Medical	38.1	48.5	+10.4	40.2
	Life Science & Industrial	14.8	15.2	+0.4	15.5
	Imaging	30.6	25.8	(4.8)	24.3
	Information & Communication	8	8.2	+0.2	8.6
Accounts Payable	Total	74.2	76.9	+2.7	82.9
	Medical	31.4	32.9	+1.5	32.6
	Life Science & Industrial	11.4	6	(5.4)	12
	Imaging	16.8	22.1	+5.3	15.1
	Information & Communication	14.6	15.9	+1.3	23.2

Note: The total balance of each item is only for the main business divisions listed above.

Summary of the Financial Report (Management Basis)

◆ Forecast of the FY Ending March 2012 (April 2011 - March 2012) (Unit: billion yen)

	(1) FY Ended March 2011 (Actual)	FY Ending March 2012			(4)-(1) Differences
		(2) First Half (Actual)	(3) Second Half (Forecast)	(4) Full Year (Forecast)	
Net Sales	851.1	416.3	373.7	790	(61.1)
Operating Income	33.7	16.9	18.7	35.6	+1.9
OP ratio to sales	4.0%	4.1%	5.0%	4.5%	+0.5%
Exchange Rate					
USD	85.72 yen	79.82 yen	80.00 yen	79.91 yen	(5.81) yen
EUR	113.12 yen	113.79 yen	110.00 yen	111.90 yen	(1.22) yen

(Premises)

- A certain amount of risk has been factored into the second half forecast, but we expect to secure 5.0% operating income ratio to net sales.
- Medical business had impact of the Earthquake in the first half, but we expect stable profit for the second half.
- Imaging business improved profitability from the FY ended March 2011
- Conducting cost cutting

Goodwill

◆ Goodwill Balance

(Unit: billion yen)

	Amortization period	Mar. 2008	Mar. 2009	Mar. 2010	Mar. 2011	Sept. 2011 (forecast)
Gyrus	20 Years	168.3	132	160	135.3	120.4
ITX	20 Years	47.2	22.6	20.8	23.2	22.9
Altis	10 Years	21.6	4.8	3.0	2.6	1.5
News Chef	10 Years	15.8	-	-	-	-
Humalabo	10 Years	16.9	-	-	-	-
Spiration	10 Years	-	-	-	3	2.6
Innov-X	10 Years	-	-	-	3.1	2.7
Spirus	10 Years	-	-	-	-	3
Others	5-20 Years	30	21.1	10.3	8.3	6.8
Total	5-20 Years	299.8	180.5	194.1	175.5	159.9

- As of March 2011, 80% of the goodwill balance comes from Gyrus.
- There is no signs of impairment as of March 2011, since the goodwill evaluation of Gyrus is tested in the surgical business.
- Losses incurred by investment securities etc. since around 1990s have already occurred before acquiring preferred stocks of Gyrus.
- There is a possibility that losses were not booked in appropriate periods. Correction of such figures could lead to a result that payment to Financial Advisors and buying back preferred stock would no longer exist. Which also means that goodwill (USD 418 million, about 33.4 billion yen, as of FY ended March 2011) will also disappear.

4. Financial Status

Interest-bearing Debt

◆ Transition of interest-bearing debt

(Unit: billion yen)

	FY ended Mar. 2007	FY ended Mar. 2008		FY ended Mar. 2009		FY ended Mar. 2010		FY ended Mar. 2011		FY ended Mar.2012
	Mar. 2007	Sept. 2007	Mar. 2008	Sept. 2008	Mar. 2009	Sept. 2009	Mar. 2010	Sept. 2010	Mar. 2011	Sept. 2011
Short-term borrowing	140	142.3	312	114.6	81.4	73.4	75.1	62.5	64.2	60.2
Current maturities of long-term borrowing	8.5	8.8	26.8	31.5	15.7	8.1	18.9	49.8	63.2	42.8
Long-term borrowings	173.1	166.7	177.4	362.4	412.6	450.9	437.1	425.3	411.1	452
Current maturities of bonds	0.1	30.1	35.2	5	2.03	40.3	20	0	0.2	20.2
Long-term bonds	140.5	110.5	105.4	150.3	130.2	110.2	110.4	110.3	110.1	90.1
Interest-bearing Debt	462.2	458.4	656.8	663.8	660.2	682.9	661.5	647.9	648.8	665.3
Cash and time deposits	216.6	179.6	158.3	129.7	136.9	223.4	206.8	204.8	213.6	233.1
Net Debt	245.6	278.8	498.5	534.1	523.3	449.5	454.7	443.1	435.2	432.2

Interest-bearing Debt (End of September 2011 – Consolidated)

◆ Consolidated interest-bearing debt list (by financial institution)

(Unit: billion yen)

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
Short-term borrowing	26.5	26.3	3.8	3.4	0	0	0	0.1	0	0	0	0	0	0
Long-term debt	153.7	111.5	80.1	18	17	31.3	13.1	24.9	8	4.8	0.8	3.6	1	0
Corporate bonds	47.3	5	2	0	0	10	1	0	0	0	0	0	0	45
Total	227.5	142.8	85.9	21.4	17	41.3	14.1	25	8	4.8	0.8	3.6	1	45

	O	P	Q	R	S	T	U	V	W	X	Y	Z	O	P
Short-term borrowing	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long-term debt	2.5	1	0.9	1	2	2	2	1.5	1	1	1	1	1	1
Corporate bonds	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	2.5	1	0.9	1	2	2	2	1.5	1	1	1	1	1	1

	Q	R	S	T	U	V	W	X	Y	Z	A'	B'	C'	Total
Short-term borrowing	0	0	0	0	0	0	0	0	0	0	0	0	0	60.2
Long-term debt	1	0.8	0.5	0.5	0.5	0.5	0.4	0.2	0.9	0.4	0.4	1.7	0.3	494.8
Corporate bonds	0	0	0	0	0	0	0	0	0	0	0	0	0	1,103
Total	1	0.8	0.5	0.5	0.5	0.5	0.4	0.2	0.9	0.4	0.4	1.7	0.3	665.3

Note: Short-term borrowing includes outstanding export bill. Long-term borrowing and corporate bonds both mature in one year are included.

Cash Flow

◆ Consolidated cash flow forecast

(Unit: billion yen)

	FY ended March 2011 (Actual-Closing B)	FY ending March 2012 (Forecast)	FY ending March 2013 (Reference)	FY ending March 2014 (Reference)	FY ending March 2015 (Reference)
Sales	847.1	790	790	790	790
Operating Income	35.4	35.6	35.6	35.6	35.6
(%)	4.2%	4.5%	4.5%	4.5%	4.5%
CF from operating activities	32.9	57.7	59.8	61	60.3
CF from investing activities	16.6	(40)	(40)	(40)	(40)
CF from financing activities	(37.4)	(11.3)	(57.1)	(109.5)	(94.6)
Cash flow	12.1	6.4	(37.3)	(88.5)	(74.3)
Interest-bearing debt	648.8	645.6	596.6	495.2	408.7
Cash and Deposits	213.6	219.9	182.6	94.1	19.8

Premises

On the supposition that the second half of FY ending March 2012 performance has achieved 80% of what was expected.

On the supposition that the performance after the period of FY ending March 2013 will continue to be flat.

Depreciation and amortization of goodwill are equivalent level of the period of March 2011 performance.

On the supposition that there is no new long-term borrowing.

Remarks

Commitment line : 65billion yen, 72 million pounds (9.4 billion yen/GBP=130 yen)

Cash and Time Deposits

◆ Transition of credit balance of FY ending March 2012. (Unit: billion yen)

	FY ended March 2011	FY ending March 2012						
	March	September	October	November (Forecast)	December (Forecast)	January (Forecast)	February (forecast)	March (forecast)
Olympus Corporation	105.5	143.9	123.5	129.3	103.2	107.1	109.7	119.4
HQ in US	6.2	3.1	5.9	7.8	5.8	6.1	6.5	5.7
HQ in Europe	14.3	17.4	19.7	18	18.9	20.5	20	20.8
HQ in UK	7.8	4.3	4.8	5.2	5.6	6	6.6	6.6
HQ in Asia	31.4	18.4	20.4	17.2	18.8	16.8	17.4	17.5
Others	48.4	46	48.8	48.8	49.8	49.9	49.9	49.9
Consolidation	213.6	233.1	223.1	226.3	202.1	206.4	210.1	219.9

Interest-bearing Debt

- ◆ Transition of interest-bearing debt balance of FY ending March 2012
(Unit: billion yen)

	FY ended March 2011	FY ending March 2012						
	March	September	October (Forecast)	November (Forecast)	December (Forecast)	January (Forecast)	February (forecast)	March (Forecast)
Olympus Corporation	476.3	526.3	511.7	511.7	501.3	511.7	511.7	501.3
HQ in US	23.8	18.8	19	18.5	18	17.4	16.6	17.4
HQ in Europe	0.8	0.6	0.9	0.9	0.9	0.9	0.9	0.9
HQ in UK	-	-	-	-	-	-	-	-
HQ in Asia	43.3	24.7	24.8	23.5	23	22.4	22.4	22.4
Others	104.6	94.8	97.7	96.7	94.8	94.8	99.7	103.6
Consolidation	648.8	665.3	654.1	651.3	638	647.2	651.3	645.6

Long-term Borrowings - Repayment Schedule

◆ Repayment schedule for the FY ending March 2012 (Unit: billion yen)

	FY ending March 2012								
	Balance at the end of Sept.	Oct.	Nov.	Dec.	Balance at the end of Dec.	Jan.	Feb.	Mar.	Balance at the end of Mar.
Olympus Corporation	525	(25)	–	–	500	–	–	–	500
Affiliates	80.1	–	(0.2)	(1.7)	78.2	–	(0.6)	(0.5)	77.1
Total	605.1	(25)	(0.2)	(1.7)	578.2	–	(0.6)	(0.5)	577.1

◆ Repayment schedule after the FY ending March 2013 (Unit: billion yen)

	Period of March 2013		Period of March 2014		Period of March 2015		Period of March 2016		Period of March 2017	
	During period	Balance in March	During period	Balance in March	During period	Balance in March	During period	Balance in March	During period	Balance in March
Olympus Corporation	(20)	480	(97)	383	(51.9)	331.1	(60)	271.1	(50)	221.1
Affiliates	(29)	48.1	(4.4)	43.7	(34.6)	9.1	(8.3)	0.8	–	0.8
Total	(49)	528.1	(101.4)	426.7	(86.5)	340.2	(68.3)	271.9	(50)	221.9

Note: Short-term borrowings is excluded.

Long-term borrowings and corporate bonds both mature in one year are included.

Thank you for your time.

Now we would like to answer your questions.

OLYMPUS
